Acknowledgements
We
thank Miriam Kalamian for
helpful comments.
Conflict of Interest
Statement: None declared.
References
1. Sporn
M.B. (1996). The war on
cancer. Lancet, 347, 1377–1381 [PubMed]
2. Seyfried
T.N. (2012). Cancer As a
Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons, Hoboken, NJ
3. Fidler
I.J. (2003). The pathogenesis
of cancer metastasis: the ‘seed and soil’ hypothesis revisited.Nat. Rev. Cancer, 3, 453–458 [PubMed]
4. Lazebnik
Y. (2010). What are the hallmarks
of cancer? Nat. Rev. Cancer, 10, 232–233 [PubMed]
5. Tarin
D. (2011). Cell and tissue interactions in carcinogenesis and metastasis
and their clinical significance. Semin. Cancer
Biol., 21, 72–82 [PubMed]
6. Seyfried
T.N. (2012). Confusion
surrounds the origin of cancer. In Cancer As a
Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons, Hoboken, NJ, pp. 15–29
7. Hanahan
D., et al. (2011). Hallmarks of
cancer: the next generation. Cell, 144, 646–674 [PubMed]
8. Baker
S.G., et al. (2007). Paradoxes in
carcinogenesis: new opportunities for research directions.BMC Cancer, 7, 151. [PMC free article] [PubMed]
9. Soto
A.M., et al. (2004). The somatic
mutation theory of cancer: growing problems with the paradigm? Bioessays, 26, 1097–1107 [PubMed]
10. Vogelstein
B., et al. (2013). Cancer genome
landscapes. Science, 339, 1546–1558 [PMC free article] [PubMed]
11. Alexandrov
L.B., et al. (2013). Signatures of
mutational processes in human cancer. Nature, 500, 415–421 [PMC free article] [PubMed]
12. Soto
A.M., et al. (2012). Is systems
biology a promising approach to resolve controversies in cancer research? Cancer Cell
Int., 12, 12. [PMC free article] [PubMed]
13. Seyfried
T.N., et al. (2012). Is the
restricted ketogenic diet a viable alternative to the standard of care for
managing malignant brain cancer? Epilepsy Res., 100, 310–326 [PubMed]
14. Seyfried
T.N. (2013). Cancer as a
metabolic disease: implications for novel therapeutics. Amer. Assoc. Cancer Res. Education Book, 2013, 31–36
15. Seyfried
T.N., et al. (2011). Metabolic
management of brain cancer. Biochim.
Biophys. Acta,1807, 577–594 [PubMed]
16. Seyfried
T.N., et al. (2005). Targeting energy
metabolism in brain cancer: review and hypothesis.Nutr. Metab. (Lond)., 2, 30. [PMC free article] [PubMed]
17. Seyfried
T.N., et al. (2010). Cancer as a
metabolic disease. Nutr. Metab.
(Lond)., 7, 7. [PMC free article] [PubMed]
18. Seyfried
T.N. (2012). Genes,
respiration, viruses, and cancer. In Cancer As a
Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons, Hoboken, NJ, pp. 145–176
19. Stratton
M.R. (2011). Exploring the
genomes of cancer cells: progress and promise. Science, 331, 1553–1558 [PubMed]
20. Seyfried
T.N. (2012). Nothing in
cancer biology makes sense except in the light of evolution. In Cancer As a Metabolic Disease: On the Origin, Management,
and
Prevention of Cancer. John Wiley & Sons,
Hoboken, NJ, pp. 261–275
21. Nowell
P.C. (1976). The clonal
evolution of tumor cell populations. Science, 194, 23–28[PubMed]
22. Fojo
T., et al. (2010). Biologically
targeted cancer therapy and marginal benefits: are we making too much of too
little or are we achieving too little by giving too much? Clin. Cancer
Res., 16, 5972–5980 [PubMed]
23. Rosell
R., et al. (2009). Customized
treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA
expression. PLoS One, 4, e5133. [PMC free article] [PubMed]
24. McLeod
H.L. (2013). Cancer
pharmacogenomics: early promise, but concerted effort needed.Science, 339, 1563–1566 [PMC free article] [PubMed]
25. Hardy
P.A., et al. . (2005) Reappraisal
of
the Hansemann-Boveri hypothesis on the origin of tumors. Cell Biol. Int., 29, 983–992 [PubMed]
26. Gibbs
W.W. (2003). Untangling the
roots of cancer. Sci. Am., 289, 56–65 [PubMed]
27. Hameroff
S.R. (2004). A new theory of
the origin of cancer: quantum coherent entanglement, centrioles, mitosis, and
differentiation. Biosystems., 77, 119–136 [PubMed]
28. Manchester
K. (1997). The quest by
three giants of science for an understanding of cancer.Endeavour, 21, 72–76 [PubMed]
29. Wolf
U. (1974). Theodor Boveri and his book, on the problem of the origin of
malignant tumors. In German J, editor. (ed.) Chromosomes
and Cancer, John Wiley & Sons, New York,
pp. 1–20
30. Duesberg
P., et al. (2000). Aneuploidy, the
somatic mutation that makes cancer a species of its own. Cell Motil. Cytoskeleton, 47, 81–107 [PubMed]
31. Salk
J.J., et al. (2010). Mutational
heterogeneity in human cancers: origin and consequences.Annu. Rev. Pathol., 5, 51–75 [PMC free article] [PubMed]
32. Cairns
J. (1981). The origin of human cancers. Nature, 289, 353–357 [PubMed]
33. Loeb
L.A. (2001). A mutator phenotype in cancer. Cancer Res., 61, 3230–3239 [PubMed]
34. Whitman
R.C. (1919). Somatic
mutations as a factor in the production of cancer; a critical review of von
Hansemanns’s theory of anaplasia in light of modern knowledge of genetics. J. Cancer Res., 4, 181–202
35. Nigro
J.M., et al. (1989). Mutations in the
p53 gene occur in diverse human tumour types. Nature,342, 705–708 [PubMed]
36. Fearon
E.R., et al. (1990). A genetic model
for colorectal tumorigenesis. Cell, 61, 759–767[PubMed]
37. Knudson
A.G. (2002). Cancer genetics. Am. J. Med. Genet., 111, 96–102 [PubMed]
38. Wagner
R.P. (1999). Anecdotal,
historical and critical commentaries on genetics. Rudolph Virchow and the
genetic basis of somatic ecology. Genetics, 151, 917–920 [PMC free article][PubMed]
39. Darlington
C.D. (1948) The plasmagene
theory of the origin of cancer. Br. J. Cancer, 2, 118–126 [PMC free article] [PubMed]
40. Koura
M., et al. (1982). Suppression of
tumorigenicity in interspecific reconstituted cells and cybrids. Gann, 73, 574–580 [PubMed]
41. Israel
B.A., et al. (1987). Cytoplasmic
suppression of malignancy. In Vitro Cell. Dev.
Biol., 23, 627–632 [PubMed]
42. Shay
J.W., et al. (1988). Cytoplasmic
suppression of tumorigenicity in reconstructed mouse cells.Cancer Res., 48, 830–833 [PubMed]
43. Howell
A.N., et al. (1978). Tumorigenicity
and its suppression in cybrids of mouse and Chinese hamster cell lines. Proc. Natl Acad. Sci. U. S. A., 75, 2358–2362 [PMC free article] [PubMed]
44. Jonasson
J., et al. (1977). The analysis of
malignancy by cell fusion. VIII. Evidence for the intervention of an
extra-chromosomal element. J. Cell Sci., 24, 255–263 [PubMed]
45. McKinnell
R.G., et al. (1969). Transplantation
of pluripotential nuclei from triploid frog tumors.Science, 165, 394–396 [PubMed]
46. Mintz
B., et al. (1975). Normal
genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. U. S. A., 72, 3585–3589 [PMC free article] [PubMed]
47. Li
L., et al. (2003). Mouse embryos
cloned from brain tumors. Cancer Res., 63, 2733–2736[PubMed]
48. Hochedlinger
K., et al. (2004). Reprogramming of
a melanoma genome by nuclear transplantation. Genes Dev., 18, 1875–1885 [PMC free article] [PubMed]
49. Seyfried
T.N. (2012). Mitochondria:
the ultimate tumor suppressor. In Cancer As a
Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons, Hoboken, NJ, pp. 195–205
50. Kaipparettu
B.A., et al. (2013). Crosstalk from
non-cancerous mitochondria can inhibit tumor properties of metastatic cells by
suppressing oncogenic pathways. PLoS One, 8, e61747. [PMC free article] [PubMed]
51. Elliott
R.L., et al. . (2012) Mitochondria
organelle transplantation: introduction of normal epithelial mitochondria into
human cancer cells inhibits proliferation and increases drug sensitivity.Breast Cancer Res. Treat., 136, 347–354 [PubMed]
52. Israel
B.A., et al. (1988). Cytoplasmic mediation
of malignancy. In Vitro Cell.
Dev.
Biol., 24, 487–490 [PubMed]
53. Petros
J.A., et al. (2005). mtDNA mutations
increase tumorigenicity in prostate cancer. Proc. Natl
Acad. Sci. U. S. A., 102, 719–724 [PMC free article] [PubMed]
54. Warburg
O. (1931). The Metabolism
of Tumours. Richard R. Smith, New York
55. Warburg
O. (1956). On the origin of
cancer cells. Science, 123, 309–314 [PubMed]
56. Pedersen
P.L. (2007). Warburg, me and
hexokinase 2: multiple discoveries of key molecular events underlying one of
cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated
glycolysis in the presence of oxygen. J. Bioenerg.
Biomembr., 39, 211–222 [PubMed]
57. Warburg
O. (1956). On respiratory
impairment in cancer cells. Science, 124, 269–270 [PubMed]
58. Warburg
O. (1969). Revidsed Lindau
lectures: the prime cause of cancer and prevention - Parts 1 & 2. In Burk D, editor. (ed.) Meeting of the
Nobel-Laureates. K.Triltsch, Lindau, Lake
Constance, Germany
59. Racker
E. (1972) Bioenergetics and the problem of tumor growth. Am. Sci., 60, 56–63 [PubMed]
60. Nelson
D.L., et al. (2008) Lehninger
Principles of Biochemistry W. H. Freeman, New York
61. Cuezva
J.M., et al. (2002). The bioenergetic
signature of cancer: a marker of tumor progression.Cancer Res., 62, 6674–6681 [PubMed]
62. Acebo
P., et al. (2009). Cancer abolishes
the tissue type-specific differences in the phenotype of energetic metabolism. Transl. Oncol., 2, 138–145 [PMC free article] [PubMed]
63. Weinhouse
S. (1956). On respiratory
impairment in cancer cells. Science, 124, 267–269[PubMed]
64. Koppenol
W.H., et al. (2011). Otto Warburg’s
contributions to current concepts of cancer metabolism. Nat. Rev. Cancer, 11, 325–337 [PubMed]
65. Stellingwerff
T., et al. . (2006) Hyperoxia
decreases muscle glycogenolysis, lactate production, and lactate efflux during
steady-state exercise. Am. J.
Physiol. Endocrinol. Metab., 290, E1180–E1190 [PubMed]
66. Gatenby
R.A., et al. (2004). Why do cancers
have high aerobic glycolysis? Nat. Rev. Cancer, 4, 891–899 [PubMed]
67. Pedersen
P.L. (1978). Tumor
mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res., 22, 190–274 [PubMed]
68. Chevrollier
A., et al. (2005) ANT2 expression
under hypoxic conditions produces opposite cell-cycle behavior in 143B and
HepG2 cancer cells. Mol. Carcinog., 42, 1–8 [PubMed]
69. Wijburg
F.A., et al. (1989) Studies on the
formation of lactate and pyruvate from glucose in cultured skin fibroblasts:
implications for detection of respiratory chain defects. Biochem. Int., 19, 563–570 [PubMed]
70. Tiefenthaler
M., et al. (2001) Increased
lactate production follows loss of mitochondrial membrane potential during
apoptosis of human leukaemia cells. Br. J.
Haematol., 114, 574–580[PubMed]
71. Donnelly
M., et al. (1976). Energy
metabolism in respiration-deficient and wild type Chinese hamster fibroblasts
in culture. J. Cell.
Physiol., 89, 39–51 [PubMed]
72. Fiske
B.P., et al. (2012) Seeing the
Warburg effect in the developing retina. Nat. Cell
Biol., 14, 790–791 [PubMed]
73. Prichard
J., et al. (1991) Lactate rise
detected by 1H NMR in human visual cortex during physiologic stimulation. Proc. Natl Acad. Sci. U. S. A., 88, 5829–5831 [PMC free article] [PubMed]
74. Fox
P.T., et al. (1988). Nonoxidative
glucose consumption during focal physiologic neural activity. Science, 241, 462–464 [PubMed]
75. Krasnow
N., et al. (1962) Myocardial
lactate and pyruvate metabolism. J. Clin.
Invest., 41, 2075–2085 [PMC free article] [PubMed]
76. Burk
D., et al. (1956). On respiratory impairment
in cancer cells. Science, 124, 270–272[PubMed]
77. Burk
D., et al. (1967). On the
significance of glucolysis for cancer growth, with special reference to Morris
rat hepatomas. J. Natl Cancer
Inst., 38, 839–863 [PubMed]
78. Vaupel
P., et al. (2012) Availability,
not respiratory capacity governs oxygen consumption of solid tumors. Int. J. Biochem. Cell Biol., 44, 1477–1481 [PubMed]
79. Moreno-Sánchez
R., et al. (2007). Energy
metabolism in tumor cells. FEBS J., 274, 1393–1418[PubMed]
80. Haq
R., et al. (2013) Oncogenic BRAF
regulates oxidative metabolism via PGC1α and MITF.Cancer Cell, 23, 302–315 [PMC free article] [PubMed]
81. Weinhouse
S. (1976). The Warburg
hypothesis fifty years later. Z.
Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol., 87, 115–126 [PubMed]
82. Ferreira
L.M. (2010). Cancer metabolism:
the Warburg effect today. Exp. Mol.
Pathol., 89, 372–380 [PubMed]
83. Hall
A., et al. (2013). Dysfunctional
oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis
driven by the (V600E)BRAF oncogene. Oncotarget, 4, 584–599 [PMC free article] [PubMed]
84. Hochachka
P.W., et al. (2002). Biochemical
Adaptation: Mechanism and Process in Physiological Evolution. Oxford Press, New York
85. Seyfried
T.N. (2012). Is respiration
normal in cancer cells? In Cancer As a Metabolic Disease: On the Origin, Management, and
Prevention of Cancer. John Wiley & Sons,
Hoboken, NJ, pp. 119–132
86. Ramanathan
A., et al. (2005). Perturbational
profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl Acad. Sci. U. S. A., 102,
5992–5997 [PMC free article][PubMed]
87. Seyfried
T.N. (2012). Is mitochondrial
glutamine fermentation a missing link in the metabolic theory of cancer? In Cancer As a
Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons, Hoboken, NJ, pp. 133–144
88. Chinopoulos
C., et al. (2010) Forward
operation of adenine nucleotide translocase during F0F1-ATPase reversal:
critical role of matrix substrate-level phosphorylation. FASEB J., 24, 2405–2416 [PMC free article] [PubMed]
89. Phillips
D., et al. (2009). Succinyl-CoA
synthetase is a phosphate target for the activation of mitochondrial metabolism. Biochemistry, 48, 7140–7149 [PMC free article] [PubMed]
90. Schwimmer
C., et al. (2005). Increasing
mitochondrial substrate-level phosphorylation can rescue respiratory growth of
an ATP synthase-deficient yeast. J. Biol. Chem., 280, 30751–30759 [PubMed]
91. Seyfried
T.N. (2012). Respiratory
dysfunction in cancer cells. In Cancer As a
Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons, Hoboken, NJ, pp. 73–105
92. Arismendi-Morillo
G. (2011) Electron
microscopy morphology of the mitochondrial network in gliomas and their
vascular microenvironment. Biochim.
Biophys. Acta, 1807, 602–608 [PubMed]
93. Arismendi-Morillo
G. (2009). Electron
microscopy morphology of the mitochondrial network in human cancer. Int. J. Biochem. Cell Biol., 41, 2062–2068 [PubMed]
94. Arismendi-Morillo
G.J., et al. (2008). Ultrastructural
mitochondrial pathology in human astrocytic tumors: potentials implications
pro-therapeutics strategies. J. Electron
Microsc. (Tokyo)., 57, 33–39[PubMed]
95. Galluzzi
L., et al. (2010) Mitochondrial
gateways to cancer. Mol. Aspects
Med., 31, 1–20[PubMed]
96. Kiebish
M.A., et al. (2009). In vitro growth
environment produces lipidomic and electron transport chain abnormalities in
mitochondria from non-tumorigenic astrocytes and brain tumours.ASN Neuro, 1, e00011. [PMC free article] [PubMed]
97. Kiebish
M.A., et al. (2008). Cardiolipin and
electron transport chain abnormalities in mouse brain tumor mitochondria:
lipidomic evidence supporting the Warburg theory of cancer. J. Lipid Res., 49, 2545–2556 [PMC free article] [PubMed]
98. Gonzalez
M.J., et al. (2012) The bio-energetic
theory of carcinogenesis. Med.
Hypotheses, 79, 433–439 [PubMed]
99. Benard
G., et al. (2008) Ultrastructure
of the mitochondrion and its bearing on function and bioenergetics. Antioxid. Redox Signal., 10, 1313–1342 [PubMed]
100. Shapovalov
Y., et al. (2011) Mitochondrial
dysfunction in cancer cells due to aberrant mitochondrial replication. J. Biol. Chem., 286, 22331–22338 [PMC free article] [PubMed]
101. Alirol
E., et al. (2006). Mitochondria and
cancer: is there a morphological connection?Oncogene, 25, 4706–4716 [PubMed]
102. Oudard
S., et al. (1997). Gliomas are
driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation
and mitochondrial ultrastructure. Anticancer
Res., 17, 1903–1911[PubMed]
103. Wu
S.B., et al. (2012). AMPK-mediated
increase of glycolysis as an adaptive response to oxidative stress in human
cells: implication of the cell survival in mitochondrial diseases. Biochim. Biophys. Acta, 1822, 233–247 [PubMed]
104. Fulda
S., et al. (2010) Targeting
mitochondria for cancer therapy. Nat. Rev. Drug
Discov., 9, 447–464 [PubMed]
105. Shapovalov
Y., et al. (2011) Mitochondrial
dysfunction in cancer cells due to aberrant mitochondrial replication. J. Biol. Chem., 286, 22331–22338 [PMC free article] [PubMed]
106. Chance
B., et al. (1959). Spectroscopic
evidence of metabolic control. Science, 129, 700–708[PubMed]
107. Colowick
S.P. (1961). The status of
Warburg’s theory of glycolysis and respiration in tumors.Quart. Rev. Biol., 36, 273–276
108. Cairns
R.A., et al. (2011) Regulation of
cancer cell metabolism. Nat. Rev.
Cancer, 11, 85–95[PubMed]
109. Ward
P.S., et al. (2012). Metabolic
reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell, 21, 297–308 [PMC free article] [PubMed]
110. Vander
Heiden M.G., et al. (2009). Understanding
the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029–1033 [PMC free article] [PubMed]
111. Rossignol
R., et al. (2004). Energy substrate
modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res., 64, 985–993 [PubMed]
112. Chevrollier
A., et al. (2011) Adenine
nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism. Biochim. Biophys. Acta, 1807, 562–567 [PubMed]
113. Jahnke
V.E., et al. (2010). Evidence for
mitochondrial respiratory deficiency in rat rhabdomyosarcoma cells. PLoS One, 5, e8637. [PMC free article] [PubMed]
114. Schild
L., et al. (2012) Composition of
molecular cardiolipin species correlates with proliferation of lymphocytes. Exp. Biol. Med. (Maywood)., 237, 372–379 [PubMed]
115. Kocherginsky
N. (2009). Acidic lipids,
H(+)-ATPases, and mechanism of oxidative phosphorylation. Physico-chemical
ideas 30 years after P. Mitchell’s Nobel Prize award. Prog. Biophys. Mol. Biol., 99, 20–41 [PubMed]
116. Claypool
S.M., et al. (2012) The complexity
of cardiolipin in health and disease. Trends
Biochem. Sci., 37, 32–41 [PMC free article] [PubMed]
117. Zu
X.L., et al. (2004). Cancer
metabolism: facts, fantasy, and fiction. Biochem.
Biophys. Res. Commun., 313, 459–465 [PubMed]
118. Wang
T., et al. (1976). Aerobic
glycolysis during lymphocyte proliferation. Nature, 261, 702–705 [PubMed]
119. Lunt
S.Y., et al. (2011) Aerobic
glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol., 27, 441–464 [PubMed]
120. Papandreou
I., et al. (2011) Anticancer drugs
that target metabolism: is dichloroacetate the new paradigm? Int. J. Cancer, 128, 1001–1008 [PubMed]
121. Burk
D., et al. (1941). Metabolism of
butter yellow rat liver cancers. Canc. Res., 1, 733–734
122. Simek
J., et al. (1965). Effect of
glucose administered in vivo or in vitro on the
respiratory quotient of rat liver tissue after partial hepatectomy. Nature, 207, 761–762 [PubMed]
123. Diatlovitskaia
E.V., et al. (1972). [Cardiolipins of
mitochondria and microsomes of Jensen’s sarcoma]. Dokl. Akad. Nauk SSSR, 206, 737–739 [PubMed]
124. Diatlovitskaia
E.V., et al. (1976). [Positional
distribution of fatty acids in the phospholipids of regenerating rat liver]. Biokhimiia., 41, 538–542 [PubMed]
125. Crabtree
H.G. (1929). Observations on
the carbohydrate metabolism of tumours. Biochem. J.,23, 536–545 [PMC free article] [PubMed]
126. Redman
E.K., et al. (2013) Role of p90(RSK)
in regulating the Crabtree effect: implications for cancer. Biochem. Soc. Trans., 41, 124–126 [PMC free article] [PubMed]
127. Díaz-Ruiz
R., et al. (2008) Mitochondrial
oxidative phosphorylation is regulated by fructose 1,6-bisphosphate. A possible
role in Crabtree effect induction? J. Biol. Chem., 283, 26948–26955[PubMed]
128. Diaz-Ruiz
R., et al. (2011) The Warburg and
Crabtree effects: on the origin of cancer cell energy metabolism and of yeast
glucose repression. Biochim.
Biophys. Acta, 1807, 568–576 [PubMed]
129. Holleran
A.L., et al. (1995) Glutamine
metabolism in AS-30D hepatoma cells. Evidence for its conversion into lipids
via reductive carboxylation. Mol. Cell.
Biochem., 152, 95–101 [PubMed]
130. Fendt
S.M., et al. (2013) Reductive
glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in
cells. Nat. Commun., 4, 2236. [PMC free article] [PubMed]
131. Pollard
P.J., et al. (2003). The TCA cycle
and tumorigenesis: the examples of fumarate hydratase and succinate
dehydrogenase. Ann. Med., 35, 632–639 [PubMed]
132. Gottlieb
E., et al. (2005). Mitochondrial
tumour suppressors: a genetic and biochemical update.Nat. Rev. Cancer, 5, 857–866 [PubMed]
133. Seyfried
T.N. (2012). Cancer models. In Cancer As a Metabolic Disease: On the Origin, Management, and
Prevention of Cancer. John Wiley & Sons,
Hoboken, NJ, pp. 31–46
134. Ecsedy
J.A., et al. (1999). Expression of
mouse sialic acid on gangliosides of a human glioma grown as a xenograft in
SCID mice. J. Neurochem., 73, 254–259 [PubMed]
135. Chou
H.H., et al. (1998). A mutation in
human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl Acad. Sci. U. S. A., 95, 11751–11756 [PMC free article][PubMed]
136. Martin
M.J., et al. (2005). Human embryonic
stem cells express an immunogenic nonhuman sialic acid. Nat. Med., 11, 228–232 [PubMed]
137. Davies
B., et al. (1993) Physiological
parameters in laboratory animals and humans. Pharm. Res., 10, 1093–1095 [PubMed]
138. Mahoney
L.B., et al. (2006). Caloric
restriction in C57BL/6J mice mimics therapeutic fasting in humans. Lipids Health Dis., 5, 13. [PMC free article] [PubMed]
139. Tentler
J.J., et al. (2012) Patient-derived
tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol., 9, 338–350 [PMC free article] [PubMed]
140. Chaparro
R.J., et al. (2006). Nonobese
diabetic mice express aspects of both type 1 and type 2 diabetes. Proc. Natl Acad. Sci. U. S. A., 103, 12475–12480 [PMC free article] [PubMed]
141. Seyfried
T.N. (2012). Mitochondrial
respiratory dysfunction and the extrachromosomal origin of cancer. In Cancer As a Metabolic Disease: On the Origin, Management,
and
Prevention of Cancer. John Wiley & Sons,
Hoboken, NJ, pp. 253–259
142. Hu
Y., et al. (2012). K-ras(G12V)
transformation leads to mitochondrial dysfunction and a metabolic switch from
oxidative phosphorylation to glycolysis. Cell Res., 22, 399–412 [PMC free article] [PubMed]
143. Neuzil
J., et al. (2012) K-Ras and
mitochondria: dangerous liaisons. Cell Res., 22, 285–287 [PMC free article] [PubMed]
144. Szent-Györgyi
A. (1977). The living state
and cancer. Proc. Natl
Acad. Sci. U. S. A., 74, 2844–2847 [PMC free article] [PubMed]
145. Pawelek
J.M., et al. (2008). The cancer
cell–leukocyte fusion theory of metastasis. Adv. Cancer
Res., 101, 397–444 [PubMed]
146. Seyfried
T.N., et al. (2013) On the origin of
cancer metastasis. Crit. Rev.
Oncog., 18, 43–73 [PMC free article] [PubMed]
147. Powell
A.E., et al. (2011). Fusion between
Intestinal epithelial cells and macrophages in a cancer context results in
nuclear reprogramming. Cancer Res., 71, 1497–1505 [PMC free article] [PubMed]
148. Pawelek
J.M. (2005). Tumour-cell
fusion as a source of myeloid traits in cancer. Lancet Oncol.,6, 988–993 [PubMed]
149. Malkin
D., et al. (1990). Germ line p53
mutations in a familial syndrome of breast cancer, sarcomas, and other
neoplasms. Science, 250, 1233–1238 [PubMed]
150. Funes
J.M., et al. (2007). Transformation
of human mesenchymal stem cells increases their dependency on oxidative
phosphorylation for energy production. Proc. Natl
Acad. Sci. U. S. A., 104, 6223–6228 [PMC free article] [PubMed]
151. Sung
H.J., et al. (2011). Mitochondrial
respiration protects against oxygen-associated DNA damage. Nat Commun, 1, 1–8 [PMC free article] [PubMed]
152. Lago
C.U., et al. (2011) p53, aerobic
metabolism, and cancer. Antioxid.
Redox Signal., 15, 1739–1748 [PMC free article] [PubMed]
153. Matoba
S., et al. (2006). p53 regulates
mitochondrial respiration. Science, 312, 1650–1653[PubMed]
154. Zhou
S., et al. (2003). Mitochondrial
impairment in p53-deficient human cancer cells.Mutagenesis, 18, 287–292 [PubMed]
155. Lee
A.C., et al. (1999). Ras proteins
induce senescence by altering the intracellular levels of reactive oxygen
species. J. Biol. Chem., 274, 7936–7940 [PubMed]
156. Weinberg
F., et al. (2010). Mitochondrial
metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. U. S. A., 107,
8788–8793 [PMC free article][PubMed]
157. Yang
D., et al. (2010). Impairment of
mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L). Cancer Biol. Ther., 9, 122–133 [PMC free article] [PubMed]
158. Moiseeva
O., et al. (2009). Mitochondrial
dysfunction contributes to oncogene-induced senescence. Mol. Cell. Biol., 29, 4495–4507 [PMC free article] [PubMed]
159. Seyfried
T.N. (2012). Respiratory
insufficiency, the retrograde response, and the origin of cancer. In Cancer As a Metabolic Disease: On the Origin, Management,
and
Prevention of Cancer. John Wiley & Sons,
Hoboken, NJ, pp. 177–194
160. Guha
M., et al. (2013) Mitochondrial
retrograde signaling at the crossroads of tumor bioenergetics, genetics and
epigenetics. Mitochondrion, 13, 577–591 [PMC free article] [PubMed]
161. Singh
K.K., et al. (2005). Inter-genomic
cross talk between mitochondria and the nucleus plays an important role in
tumorigenesis. Gene, 354, 140–146 [PubMed]
162. Jazwinski
S.M. (2005). The retrograde
response links metabolism with stress responses, chromatin-dependent gene
activation, and genome stability in yeast aging. Gene, 354, 22–27[PubMed]
163. Nargund
A.M., et al. (2012). Mitochondrial
import efficiency of ATFS-1 regulates mitochondrial UPR activation. Science, 337, 587–590 [PMC free article] [PubMed]
164. Al
Mamun A.A., et al. (2012). Identity and
function of a large gene network underlying mutagenic repair of DNA breaks. Science, 338, 1344–1348 [PMC free article] [PubMed]
165. Dang
C.V. (2010). Glutaminolysis: supplying carbon or nitrogen or both for cancer
cells? Cell Cycle, 9, 3884–3886 [PubMed]
166. Bissell
M.J., et al. (2011). Why don’t we get
more cancer? A proposed role of the microenvironment in restraining cancer
progression. Nat. Med., 17, 320–329 [PMC free article][PubMed]
167. Gatenby
R.A., et al. (2007). Glycolysis in
cancer: a potential target for therapy. Int. J. Biochem.
Cell Biol., 39, 1358–1366 [PubMed]
168. Husain
Z., et al. (2013) Tumor-derived
lactate modifies antitumor immune response: effect on myeloid-derived
suppressor cells and NK cells. J. Immunol., 191, 1486–1495 [PubMed]
169. Liu
E.T. (2013). Grappling with cancer. Science, 339, 1493. [PubMed]
170. Pennisi
E. (2013). Steering cancer
genomics into the fast lane. Science, 339, 1540–1542[PubMed]
171. Stratton
M.R., et al. (2009). The cancer
genome. Nature, 458, 719–724 [PMC free article][PubMed]
172. Crespi
B., et al. (2005). Evolutionary
biology of cancer. Trends Ecol.
Evol., 20, 545–552[PubMed]
173. Merlo
L.M., et al. (2006). Cancer as an
evolutionary and ecological process. Nat. Rev.
Cancer,6, 924–935 [PubMed]
174. Davies
P.C., et al. (2011). Cancer tumors as
Metazoa 1.0: tapping genes of ancient ancestors.Phys. Biol., 8, 015001. [PMC free article] [PubMed]
175. Mayer
E. (1982). Evolution before Darwin. In The Growth of
Biological Thought: Diversity, Evolution, and Inheritance. Belknap Harvard, Cambridge, MA, pp. 343–362
176. Handel
A.E., et al. (2010). Is Lamarckian
evolution relevant to medicine? BMC Med. Genet.,11, 73. [PMC free article] [PubMed]
177. Koonin
E.V., et al. (2009). Is evolution
Darwinian or/and Lamarckian? Biol. Direct, 4, 42. [PMC free article] [PubMed]
178. Smiraglia
D.J., et al. (2008). A novel role for
mitochondria in regulating epigenetic modification in the nucleus. Cancer Biol. Ther., 7, 1182–1190 [PMC free article] [PubMed]
179. Minocherhomji
S., et al. (2012) Mitochondrial
regulation of epigenetics and its role in human diseases. Epigenetics, 7, 326–334 [PMC free article] [PubMed]
180. Feinberg
A.P., et al. (2004). The history of
cancer epigenetics. Nat. Rev.
Cancer, 4, 143–153[PubMed]
181. Pawelek
J.M. (2000). Tumour cell
hybridization and metastasis revisited. Melanoma Res., 10, 507–514 [PubMed]
182. Huysentruyt
L.C., et al. (2010). Perspectives on
the mesenchymal origin of metastatic cancer.Cancer Metastasis Rev., 29, 695–707 [PMC free article] [PubMed]
183. Holmgren
L., et al. (1999). Horizontal
transfer of DNA by the uptake of apoptotic bodies.Blood, 93, 3956–3963 [